Sonidegib对安非他酮和华法林药代动力学的影响
这项多中心开放标签研究在晚期实体瘤患者中评估sonidegib 800 mg每日一次对CYP2C9探针华法林和CYP2B6探针安非他酮药代动力学的影响。结果显示,sonidegib对华法林药效学和安非他酮药代动力学均无临床显著影响。
要点
- Sonidegib 800 mg每日一次不影响华法林(CYP2C9探针)的药代动力学或药效学。
- Sonidegib 800 mg每日一次不影响安非他酮(CYP2B6探针)的药代动力学。
- Sonidegib 800 mg的安全性特征与200 mg相似,且不受单剂探针药物影响。
核心结论
- Sonidegib 800 mg每日一次(高于FDA批准剂量)未影响华法林的药代动力学或药效学,也未影响安非他酮的药代动力学。
研究设计与样本
- 多中心、开放标签研究,在晚期实体瘤患者中评估sonidegib对探针药物药代动力学的影响。
- 队列1患者在第1天(导入期)和sonidegib治疗第2周期第22天(C2D22)接受单剂华法林15 mg。
- 队列2患者在第1天(导入期)和C2D22接受单剂安非他酮75 mg。
- 两队列均在导入期后开始sonidegib 800 mg每日一次口服,28天为一周期。
主要发现
- (S)-华法林:AUCinf几何均值比[90%CI]为1.15 [1.07, 1.24],Cmax为0.88 [0.81, 0.97](联用sonidegib vs 不联用)。
- (R)-华法林:AUCinf几何均值比为1.10 [0.98, 1.24],Cmax为0.93 [0.87, 1.0](联用sonidegib vs 不联用)。
- 安非他酮:AUCinf几何均值比为1.10 [0.99, 1.23],Cmax为1.16 [0.95, 1.42](联用sonidegib vs 不联用)。
临床怎么用
- 临床使用sonidegib 800 mg每日一次时,预计不会对华法林或安非他酮的暴露产生临床显著影响。
- Sonidegib 800 mg的安全性特征与200 mg相似,且不受单剂华法林或安非他酮影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We evaluated the potential effect of sonidegib at an oral dose of 800 mg once daily (QD) on the pharmacokinetics (PK) of the probe drugs warfarin (CYP2C9) and bupropion (CYP2B6). METHODS: This was a multicentre, open-label study to evaluate the effect of sonidegib on the PK of the probe drugs warfarin and bupropion in patients with advanced solid tumours. Cohort 1 patients received a single warfarin 15-mg dose on Day 1 of the run-in period and on Cycle 2 Day 22 (C2D22) of sonidegib administration. Cohort 2 patients received a single bupropion 75-mg dose on Day 1 of run-in period and on C2D22 of sonidegib administration. Sonidegib 800 mg QD oral dosing began on Cycle 1 Day 1 of a 28-day cycle after the run-in period in both cohorts. RESULTS: The geometric means ratios [90% confidence interval] for (S)-warfarin with and without sonidegib were: area under the concentration-time curve from time 0 to infinity (AUCinf ) 1.15 [1.07, 1.24] and maximum plasma concentration (Cmax ) 0.88 [0.81, 0.97]; and for (R)-warfarin were: AUCinf 1.10 [0.98, 1.24] and Cmax 0.93 [0.87, 1.0]. The geometric means ratios [90% confidence interval] of bupropion with and without sonidegib were: AUCinf 1.10 [0.99, 1.23] and Cmax 1.16 [0.95, 1.42]. Sonidegib 800 mg had a safety profile that was similar to that of lower dose sonidegib 200 mg and was unaffected by single doses of the probe drugs. CONCLUSIONS: Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate).
引用
- Pooler DB, Ness DB, Sarantopoulos J, et al. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2020. PMID: 32736411. doi:10.1111/bcp.14508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。